Letter from the Editor

Dear colleagues,

 

Like last year`s EAN meeting and almost any of the big international congresses, EAN 2021 was again held as a virtual meeting. So, while the splendour of Vienna and the chats in the Kaffeehäuser (coffee houses) were missed, the extensive program provided a very up-to-date overview of our quickly moving field.

Much news was communicated regarding diagnostic, therapeutic, and pathogenetic advances in subdisciplines like multiple sclerosis, movement disorders, epilepsy, the dementias, and neuromuscular disorders. Appropriately, one focus was on COVID-19, its nervous system manifestations, vaccinations, and specific management issues.

There were lively discussions during live Q&A sessions and in the chatrooms.

As always, the main meeting was preceded by a range of excellent teaching courses providing high level postgraduate educational sessions.

 

I hope you will find this report highlighting some outstanding contributions useful.

We all expect and long for a face-to-face meeting at EAN 2022.

 

With best wishes,

Hans-Peter Hartung MD FRCP FAAN FANA FEAN



 

Biography

Prof. Hartung is currently Professor of Neurology at Heinrich-Heine-University Düsseldorf, Honorary Professor at Brain and Mind Center, University of Sydney, Visiting Professor at Medical University Vienna and Palacky University Olomouc. He was chairman of the Department of Neurology, Heinrich-Heine-University Düsseldorf from 2001-2020, director of the Center for Neurology and Neuropsychiatry from 2012-2020 and director of the Department of Conservative Medicine from 2012-2019.

Prof. Hartung’s clinical and translational research interests are in the field of basic and clinical neuroimmunology and in particular multiple sclerosis and immune neuropathies, development of new immunological, neuroprotective and neural repair promoting strategies. He has (co-)authored more than 950 articles in peer-reviewed journals and 100 book chapters. He has been involved as member of the Steering Committee in numerous international multicentre therapeutic phase 2 and 3 trials in multiple sclerosis, Guillain-Barré Syndrome and CIDP.

He was President of ECTRIMS and has served/serves amongst others on the executive boards of the European Charcot Foundation, the European Neurological Society, and the International Multiple Sclerosis Cognition Society (IMSCOGS). He is/was also member of the Editorial Board of a number of international journals. Prof. Hartung is a Fellow of the AAN and EAN, and has been chair/member of the management group of the EAN scientific panels on general neurology and multiple sclerosis. He is Corresponding and Honorary Fellow of several international societies.

Conflict of Interest Statement:

Hans-Peter Hartung has received fees for consulting, speaking, and serving on steering committees from Bayer Healthcare, Biogen, GeNeuro, MedImmune, Merck, Novartis, Opexa, Receptos Celgene, Roche, Sanofi Genzyme, CSL Behring, Octapharma, Teva, TG Therapeutics, and Viela Bio, with approval by the Rector of Heinrich-Heine-University.

 

Copyright ©2021 Medicom Medical Publishers



Posted on 17 August 2021